Immix Biopharma is trading 5.76% lower at $8.18, alongside biotech-sector weakness.
- Biotech is down 2.06% during regular trading, amid broader market weakness.
- Search results showed no new company-specific announcement explaining the October 16 move; the latest company news surfaced was dated October 5.
- Recent coverage describes investor unease across biotech but does not link it to Immix Biopharma’s decline.